Anaveon To Take A Different Clinical Path With Novel IL-2 Therapy
Interleukin-2 Agonist Being Assessed In Solid tumors
Executive Summary
Anaveon of Switzerland plans to take the clinical road less travelled with its novel interleukin-2 agonist, ANV419, its CEO told Scrip as the firm launched a Phase I/II study for its lead asset.
You may also be interested in...
Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders
Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.
Finance Watch: Two Years Later, $212m More Cash For Omega’s New Life Science Fund
Private Company Edition: Omega Funds closed its seventh venture capital fund, far exceeding its $500m goal. Also, Anaveon raised a CHF110m ($119.8m) series B round, Ambys brought its series A total to $107m with $47m in additional investment and Mythic launched with a $103m series B round.
Novartis, Zurich University Spin-out Anaveon Tackles IL-2 Challenges With Fresh Funds
Syncona and Novartis Venture Fund have invested CHF35m in Anaveon, which reckons it can overcome the toxicity and half-life limitations of the cytokine interleukin-2 to enhance the body’s immune response to tumors.